Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.73 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.71 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | IKBKB | O14920 | 1/20 | 0.50 |
| ▸ | CHUK | O15111 | 1/20 | 0.50 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034675 | 0.92 | CA12 (0.74) | TSHRNPSR1SIGMAR1CA12CA2 | |
| SCHEMBL23682867 | 0.89 | CA12 (0.66) | TSHRNPSR1SIGMAR1CA12CA2 | |
| SCHEMBL12570977 | 0.86 | CA12 (0.62) | TSHRNPSR1SIGMAR1CA12CA2 | |
| SCHEMBL6130639 | 0.86 | CA12 (0.81) | TSHRNPSR1SIGMAR1CA12CA2 | |
| SCHEMBL9577239 | 0.85 | SIGMAR1 (0.68) | SIGMAR1CA2GAAALDH1A1 | |
| SCHEMBL7028080 | 0.84 | TSHR (0.71) | TSHRNPSR1SIGMAR1CA12CA2 | |
| SCHEMBL4065569 | 0.84 | TSHR (0.71) | TSHRNPSR1SIGMAR1CA12CA2 | |
| SCHEMBL3327488 | 0.84 | TSHR (0.71) | TSHRNPSR1SIGMAR1CA12CA2 | |
| SCHEMBL19152453 | 0.84 | TSHR (0.71) | TSHRNPSR1SIGMAR1CA12CA2 | |
| SCHEMBL19563408 | 0.84 | SIGMAR1 (0.71) | TSHRNPSR1SIGMAR1CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | claimed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | claimed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | claimed |
| US-12496302-B2 | Compositions and methods for the treatment and diagnosis of cancer | THE GENERAL HOSPITAL CORPORATION (US) | 2025-12-16 | — | — | US | disclosed |
| US-20240066033-A1 | Compositions and Methods for the Treatment and Diagnosis of Cancer | BIOVENTURES, LLC | 2024-02-29 | — | — | US | disclosed |
| US-20240066033-A1 | Compositions and Methods for the Treatment and Diagnosis of Cancer | BIOVENTURES, LLC | 2024-02-29 | — | — | US | disclosed |
| US-20240066033-A1 | Compositions and Methods for the Treatment and Diagnosis of Cancer | BIOVENTURES, LLC | 2024-02-29 | — | — | US | disclosed |
| US-20240000784-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF CANCER | BIOVENTURES, LLC | 2024-01-04 | — | — | US | disclosed |
| US-11787781-B2 | Inhibiting ataxia telangiectasia and RAD3-related protein (ATR) | CELATOR PHARMACEUTICALS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787781-B2 | Inhibiting ataxia telangiectasia and RAD3-related protein (ATR) | CELATOR PHARMACEUTICALS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2022032224-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2022-02-10 | — | — | WO | disclosed |
| US-7446113-B2 | Acetylenyl-pyrazolo-pyrimidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-11-04 | — | — | US | disclosed |
| EP-1863818-A1 | ACETYLENYL-PYRAZOLO-PVRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| US-20070167460-A1 | Acetylenyl-pyrazolo-pyrimidine derivatives | MCARTHUR SILVIA G | 2007-07-19 | — | — | US | disclosed |
| US-7238808-B2 | Acetylenyl-pyrazolo-pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20060217387-A1 | Acetylenyl-pyrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-09-28 | — | — | US | disclosed |
| WO-2006099972-A1 | ACETYLENYL-PYRAZOLO-PVRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-28 | — | — | WO | disclosed |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | disclosed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240000784-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF CANCER | RNMT, NSUN2, TRDMT1 | TSHR 4043/4885NPSR1 4617/4885SIGMAR1 4092/4885 |
| US-12496302-B2 | Compositions and methods for the treatment and diagnosis of cancer | NSUN2, RNMT, TRDMT1 | TSHR 3879/4885NPSR1 4720/4885SIGMAR1 3765/4885 |
| US-20060217387-A1 | Acetylenyl-pyrazolo-pyrimidine derivatives | NAT1, TPMT, ACAT1 | TSHR 1237/4885NPSR1 767/4885SIGMAR1 2544/4885 |
| US-20070167460-A1 | Acetylenyl-pyrazolo-pyrimidine derivatives | NAT1, ADORA2B, TPMT | TSHR 1244/4885NPSR1 1021/4885SIGMAR1 2304/4885 |
| US-11787781-B2 | Inhibiting ataxia telangiectasia and RAD3-related protein (ATR) | ATR, CHEK2, CHEK1 | TSHR 3819/4885NPSR1 4801/4885SIGMAR1 4777/4885 |
| US-20240066033-A1 | Compositions and Methods for the Treatment and Diagnosis of Cancer | NSUN2, RNMT, TRDMT1 | TSHR 3879/4885NPSR1 4720/4885SIGMAR1 3765/4885 |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | GSK3A, GSK3B, PYGL | TSHR 898/4885NPSR1 591/4885SIGMAR1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.